Literature DB >> 9176556

Effects of malathion metabolites on degranulation of and mediator release by human and rat basophilic cells.

S Xiong1, K Rodgers.   

Abstract

In the present study, the effects of malathion and malathion derivatives on histamine and beta-hexosaminidase release by RBL-1 cells, rat peritoneal mast cells (RPMC), and human peripheral blood basophils (HPBB) and cutaneous mast calls were examined. One hour of incubation of RBL-1 cells with all organophosphate compounds tested, except for malathion and malathion monoacid, led to an increase in histamine release. beta-Hexosaminidase, an enzyme released by basophilic cells and a biochemical marker of degranulation, was not released from RBL-1 cells after 1 h of exposure to organophosphate compounds. Within 4 h, all compounds tested increased the release of histamine and beta-hexosaminidase. Longer exposures led to a decrease in the concentration of the compound that was required to cause mediator release. Exposure of RPMC to organophosphate compounds, with the exception of malathion monoacid and malathion (30 min) or malathion monoacid (1 h), led to the release of histamine, but not beta-hexosaminidase. Incubation of HPBB with malaoxon (51.4 +/- 2.8% total histamine released), malathion diacid (25.7 +/- 2.9%), beta-malathion monoacid (31.4 +/- 2.8%), and isomalathion (57.1 +/- 17.1%) for 1 h led to the release of histamine. Only malaoxon and isomalathion caused beta-hexosaminidase release from HPBB after a 1-h incubation. Incubation of cutaneous mast cells with malaoxon and beta-monoacid for 4 h led to increased release of histamine and beta-hexosaminidase at levels comparable to compound 48/80. These data suggest that malathion metabolites can cause rapid release of histamine from basophilic cells from a variety of origins and species. With prolonged incubation, malathion itself caused the release of mast-cell mediators, suggesting that the cells may be capable of metabolizing malathion. These data also indicate a disparity between the release kinetics of two different mast-cell mediators contained in granules by organophosphates, and that there are different mechanisms of mediator release.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176556     DOI: 10.1080/00984109708984019

Source DB:  PubMed          Journal:  J Toxicol Environ Health        ISSN: 0098-4108


  6 in total

Review 1.  A review of experimental evidence linking neurotoxic organophosphorus compounds and inflammation.

Authors:  Christopher N Banks; Pamela J Lein
Journal:  Neurotoxicology       Date:  2012-02-10       Impact factor: 4.294

2.  Organophosphorus pesticides decrease M2 muscarinic receptor function in guinea pig airway nerves via indirect mechanisms.

Authors:  Becky J Proskocil; Donald A Bruun; Charles M Thompson; Allison D Fryer; Pamela J Lein
Journal:  PLoS One       Date:  2010-05-10       Impact factor: 3.240

3.  Protective effects of the antihistamine promethazine aginst acute paraxon-methyl and dicrotophos toxicity in adult rats.

Authors:  Syed M Nurulain; Shreesh Ojha; Mohammad Shafiullah; Nadia Khan; Murat Oz; Bassem Sadek
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Ragweed pollen-mediated IgE-independent release of biogenic amines from mast cells via induction of mitochondrial dysfunction.

Authors:  Grzegorz Chodaczek; Attila Bacsi; Nilesh Dharajiya; Sanjiv Sur; Tapas K Hazra; Istvan Boldogh
Journal:  Mol Immunol       Date:  2009-06-06       Impact factor: 4.407

Review 5.  Mechanisms of organophosphorus pesticide toxicity in the context of airway hyperreactivity and asthma.

Authors:  Frances C Shaffo; Ana Cristina Grodzki; Allison D Fryer; Pamela J Lein
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-28       Impact factor: 5.464

6.  Antigen sensitization influences organophosphorus pesticide-induced airway hyperreactivity.

Authors:  Becky J Proskocil; Donald A Bruun; Jesse K Lorton; Kirsten C Blensly; David B Jacoby; Pamela J Lein; Allison D Fryer
Journal:  Environ Health Perspect       Date:  2008-03       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.